Total number of categories
Total number of articles
Review of price tag for Spark Therapeutics’ gene therapy treatment (Luxturna, $850,000 per patient) suggests a discount of up to 90% in certain cases.
In a report published by the US Institute for Clinical and Economic Review (ICER), healthcare experts stated that the recently approved gene therapy for Leber’s congenital amaurosis (LCA), “Luxturna voretigene neparvovec-rzyl”, from Spark Therapeutics Inc. (NASDAQ:ONCE), may require substantial discounts in order to be cost-effective. The new drug, developed by Spark Therapeutics, a gene therapy […]Read full story
Biomarkers of metabolism, easily detectable with SD-OCT, indicate association with successful treatment of DME with DEX implant.
Collaborative clinical research by clinicians based in Tel Aviv University, Israel, University of Buenos Aires, Argentina, the University of Leipzig, Germany and the University of Milan, Italy have shown that certain SD-OCT biomarkers may act as useful image findings pointers in DEX treatment of diabetic macular edema (DME). The research, carried out on a total […]Read full story
CRISPR / Cas 9 gene editing technology shows promising anti-VEGF affects in lab models of angiogenesis.
Researchers, led by investigators at the Schepens Eye Research Institute of Massachusetts Eye and Ear, and the Department of Ophthalmology, Harvard Medical School, Boston, have shown that recently developed gene editing technology is capable of depleting VEGF2 expression demonstrating a potential therapeutic approach to retinal angiogenesis. The technology, commonly referred to as CRISPR / Cas […]Read full story
January 19th, 2018: “EURETINA-Brief”© Issue No. 169
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 19th, 2018 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]Read full story
Whole exome sequencing (WES) continues to yield significant efficiencies in clinical identification of inherited retinal degenerations.
Research results reported by investigators based at the Department of Genetics & Microbiology, University of Barcelona, Spain, have shown that whole exome sequencing (WES) continues to provide efficient returns in the identification of the genetic diagnosis for a range of inherited retinal disorders. The Spanish research group worked on a cohort of 33 families with […]Read full story
Findings from an international genomics consortium almost double the number of associated genetic loci and variants for AMD
Research conducted by the International AMD Genomics Consortium (IAMDGC) has recently reported an almost doubling in the number of genetic risk loci associated with age-related macular degeneration (AMD). In a significant publication in the journal Nature Genetics, the research group has reported on an analysis of >12 million gene variants, “including 163,714 directly genotyped, mostly […]Read full story